Company: SRPT
Filing Date: 2025-07-16
Form Type: 8-K
Source: 0000950170-25-096257
Chunk: 2

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-07-16
Form: 8-K
Item: Item 5.02
Chunk 2
---
 2020, she served as our Senior Vice President, Gene Therapy. Prior to joining the Company, she served as the head of the Laboratory for Gene Therapy Research at Nationwide Children’s Hospital and co-founded and served as chief scientific officer of Myonexus Therapeutics before it was acquired by the Company in 2019. She is a National Institutes of Health (NIH) Fellow appointee and is a current board member of the Association for Regenerative Medicine, as well as a member of the American Society for Gene and Cell Therapy, and the American Academy of Neurology. She holds a Bachelor of Science degree in biology from Kings College and a Ph. D. in molecular genetics from Ohio State University.

In connection with her appointment and expanded responsibilities, Dr. Rodino-Klapac’s base salary will be increased to $800,000 and her target annual bonus will be increased to 65% of her base salary.

Mr. Wong, age 46, has served as the Company’s Senior Vice President, Strategic Finance, Treasury and Investor Relations since March 2025. From March 2022 to March 2025, he served as Vice President, Financial Strategy, Planning & Analysis and Treasury.

Mr. Wong joined the Company as Vice President, Financial Strategy, Planning & Analysis in July 2021. From June 2017 to July 2021, Mr. Wong worked at GW Pharmaceuticals plc, most recently as Vice President, Finance. He holds a Bachelor of Arts degree in Chinese language and literature from University of California Irvine and a Master's degree in accounting from the University of Southern California Marshall School of Business.

In connection with his appointment, Mr. Wong will receive a base salary of $550,000 and a target annual bonus equal to 50% of his base salary.

On July 14, 2025, as part of the reduction in force, the Company terminated the employment of Dallan Murray, the Company’s Executive Vice President, Chief Customer Officer, effective July 18, 2025. The Company entered into a Separation and Consulting Agreement and General Release (the “ Agreement”), dated July 14, 2025, pursuant to which Mr. Murray will remain a consultant to the Company through January 17, 2026. Pursuant to the terms of the applicable equity award agreements, the outstanding equity awards issued to Mr. Murray as of July 14, 2025 will continue to vest through the period in which Mr. Murray continues to provide consulting services to the Company. Under the